While TLR stimulation in CD8+ T cells has been shown to bolster antitumor responses, transient expression of TLRs on CD8+ T cells and difficulties with agonist infiltration into solid tumors, have narrowed the therapeutic potential of TLR agonists in cancer. Here, CD8A is linked to cancer.